Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
© 2022. The Author(s)..
A steep rise in Omicron reinfection cases suggests that this variant has increased immune evasion ability. To evaluate its antigenicity relationship with other variants, antisera from guinea pigs immunized with spike protein of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were cross-tested against pseudotyped variants. The neutralization activity against Omicron was markedly reduced when other VOCs or VOIs were used as immunogens, and Omicron (BA.1)-elicited sera did not efficiently neutralize the other variants. However, a Beta or Omicron booster, when administered as the 4th dose 3-months after the 3rd dose of any of the variants, could elicit broad neutralizing antibodies against all of the current variants including Omicron BA.1. Further analysis with 280 available antigen-antibody structures and quantification of immune escape from 715 reported neutralizing antibodies provide explanations for the observed differential immunogenicity. Three distinct clades predicted using an in silico algorithm for clustering of sarbecoviruses based on immune escape provide key information for rational design of vaccines.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
---|---|
Enthalten in: |
Signal transduction and targeted therapy - 7(2022), 1 vom: 27. Juli, Seite 256 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Qianqian [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Viral |
---|
Anmerkungen: |
Date Completed 29.07.2022 Date Revised 31.08.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41392-022-01123-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM344162885 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM344162885 | ||
003 | DE-627 | ||
005 | 20231226022129.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41392-022-01123-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1147.xml |
035 | |a (DE-627)NLM344162885 | ||
035 | |a (NLM)35896529 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Qianqian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.07.2022 | ||
500 | |a Date Revised 31.08.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a A steep rise in Omicron reinfection cases suggests that this variant has increased immune evasion ability. To evaluate its antigenicity relationship with other variants, antisera from guinea pigs immunized with spike protein of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were cross-tested against pseudotyped variants. The neutralization activity against Omicron was markedly reduced when other VOCs or VOIs were used as immunogens, and Omicron (BA.1)-elicited sera did not efficiently neutralize the other variants. However, a Beta or Omicron booster, when administered as the 4th dose 3-months after the 3rd dose of any of the variants, could elicit broad neutralizing antibodies against all of the current variants including Omicron BA.1. Further analysis with 280 available antigen-antibody structures and quantification of immune escape from 715 reported neutralizing antibodies provide explanations for the observed differential immunogenicity. Three distinct clades predicted using an in silico algorithm for clustering of sarbecoviruses based on immune escape provide key information for rational design of vaccines | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Membrane Glycoproteins |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a Viral Envelope Proteins |2 NLM | |
650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
700 | 1 | |a Liang, Ziteng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
700 | 1 | |a Liu, Shuo |e verfasserin |4 aut | |
700 | 1 | |a Li, Tao |e verfasserin |4 aut | |
700 | 1 | |a Yu, Yuanling |e verfasserin |4 aut | |
700 | 1 | |a Cui, Qianqian |e verfasserin |4 aut | |
700 | 1 | |a Wu, Xi |e verfasserin |4 aut | |
700 | 1 | |a Nie, Jianhui |e verfasserin |4 aut | |
700 | 1 | |a Wu, Jiajing |e verfasserin |4 aut | |
700 | 1 | |a Cui, Zhimin |e verfasserin |4 aut | |
700 | 1 | |a Lu, Qiong |e verfasserin |4 aut | |
700 | 1 | |a Wang, Xiangxi |e verfasserin |4 aut | |
700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 7(2022), 1 vom: 27. Juli, Seite 256 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:27 |g month:07 |g pages:256 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-022-01123-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 7 |j 2022 |e 1 |b 27 |c 07 |h 256 |